November 30, 2007

Pharmaceuticals and the Economy of Medical Knowledge

By JEREMY A. GREENE

Newspaper headlines over the past few months have documented the downfall of Avandia, a promising and widely prescribed drug for diabetes now linked to increased mortality from heart attacks. Roughly a million Americans were taking Avandia before the news of the side effects broke, and the public now wants to know why so many people were allowed to consume a potentially harmful compound for so long. Like Vioxx, Avandia has become a flash point in the public debate over the risks of new

Digital or Print Subscription

Web Pass

Already have an account? Log In Now.